StockWatch
·
LAURUS LABS LTD · QQ2 FY-2027 · THE CALL

Record Q2 growth, but capex surge and Q3 softness cloud near-term

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

Q2 FY27 resultsLAURUSLABSLaurus Labs Ltd03 Nov 2026 · 6 min read
Verdict

Hold

confidence 7/10

Credibility

Grade B

Hit Q2 revenue/profit vs. delivered; margin guidance sustained; capex raised (not maintained); Q3 headwind disclosed upfront (credibility positive).

Short-term outlook

Cautiously Optimistic

next 1–2 quarters

Long-term outlook

Optimistic

multi-year

Record Q2 (₹2,206 Cr, +33% YoY, NPM 19.6%) validates guidance and shows structural CDMO strength (86% growth). But ₹3K capex raise, flagged Q3 softness (Laurus Bio ramp-down), and unquantified peptide timeline (validations 12–18 months, revenue '28) create near-term FCF headwind. Long-term trajectory (CDMO 50% by FY30, ROCE 19%→25%) is credible but depends on execution.

₹2206.4 Cr

Revenue · +33.4% YoY

₹436.2 Cr

Reported PAT · +124.3% YoY

Expanding

Margins · vs guidance: Corroborated

Did the claims hold up?

Management's claims vs. the numbers

Q2 total revenue ₹2,206 Cr, highest ever

MET

Delivered ₹2,206.4 Cr; YoY +33.4%, QoQ +8.9%

CDMO 86% growth in Q2 with sales ₹875 Cr

MET

H1 CDMO ₹1,710 Cr (77% growth YoY); 125 active programs delivering

Gross margin 63%, EBITDA margin 34.5% in Q2

MET

Delivered OPM 34%, gross margin~63%; margin expansion from Q1

PAT ₹441 Cr in Q2 vs ₹809 Cr in H1

MET

Delivered Q2 PAT ₹436.2 Cr; NPM 19.6%, consistent with call

Capex ₹3,000 Cr for FY27-'28 (raised from ₹2,000 Cr)

MET

H1 capex ₹864 Cr on track; raises prior guidance, aligns with expansion

Laurus Bio Q2 ₹29 Cr (down 16% YoY due to campaign phasing)

MET

Acknowledged Q3 softness; H1 ₹64 Cr vs prior ₹200 Cr illustrates tapering

Earnings quality

What changed since the last call

Deltas vs. the prior call

Capex guidance raised to ₹3,000 Cr

Upgrade

Prior FY27 guidance ₹2,000 Cr; now ₹3,000 Cr for FY27-'28 period; driven by peptide capacity, KRKA, Laurus Bio expansion

CDMO growth outpacing expectations

Upgrade

86% growth in Q2 (₹875 Cr) vs prior implied mid-40% pace; 125 active programs showing commercial traction

Margin expansion confirmed despite capex

Neutral

EBITDA 34.5% in Q2 vs 33.2% in H1; guidance 30%+ EBITDA maintained; operational leverage offsetting R&D spend

ROCE trajectory ahead of target

Upgrade

Now 22.5% for H1 vs FY26 17.7%; on track toward 25% target (prior guidance 19%→25%)

Laurus Bio near-term softness flagged

Downgrade

Q3 expected 'soft' due to validation and campaign phasing; H1 ₹64 Cr vs ₹200 Cr prior (down ~68% YoY)

The Q&A

Analysts pressed hard on peptide capacity, customer concentration, capex breakdown, and Laurus Bio trajectory. Management held firm on margin guidance, deflected on competitor-sensitive details (project specs, capex modality mix), and disclosed Q3 softness upfront. Tone: skeptical but not hostile; management credible where transparent.

The exchanges that mattered

Peptide commercialization timeline — Tushar, Motilal Oswal

Answered

Expect commercial revenues around 2-year timeframe; facilities qualified for validation campaigns; high utilization expected once approved

CDMO growth drivers Q1 to Q2 — Sajal Kapoor, Antifragile Thinking

Partial

Organic growth; programs commercializing from development to late-stage; clinical programs moving through phases; no specific one-offs called out

CDMO sequential growth quality — Chirag Shah, White Pine

Partial

Meaningful organic growth; no one-off large molecules; quality and technical capabilities adding customers; capabilities expanding

Peptide modality mix outlook — Sekhar Kadiyala, Family Office

Answered

All modalities will coexist; SPPS, LPPS, hybrid, fermentation each serve unique requirements; no single winner; ongoing expansion across all

EBITDA margin sustainability — Foram Parekh, BOB Capital

Answered

EBITDA margin improvement from operational leverage; R&D cost rationalization underway; guiding 30%+ EBITDA floor

CDMO project portfolio concentration — Rahul Bharadwaj, Individual

Dodged

Cannot disclose granular project mix; ranges from USD 200K to USD 10M; difficult to quantify revenue impact per project

Peptide facility capex and asset turns — Dhawal, Jefferies

Partial

Reactor volume ~16K liters for SPPS synthesis; validation timelines 12-18 months; strategic not to disclose capex assumptions

Peptide backward integration and customer mix — Vivek Agrawal, Citigroup

Dodged

Cannot disclose specifics due to confidentiality; customers asking for capacity; expanding based on early clinical phase programs

KRKA JV timeline and contribution — Nayan Padsala, Individual

Answered

Validation starting mid-2027; expect meaningful contributions by FY28-29 once validations complete and filings proceed

Peptide capex ballpark disclosure — Shrikant Akolkar, Nuvama

Dodged

Cannot disclose strategic reasons; customer feedback incorporated post-deliberation; no specific number given

Q2 margin sustainability forward — Krish Mehta, Enam Holdings

Answered

Committed to 60%+ gross margin and 30%+ EBITDA; guidance stands; margin profile sustainable given operational leverage

Peptide purification criticality — Alankar Garude, Kotak Institutional

Answered

Purification and isolation equally important as synthesis; investing in downstream capabilities; building integrated value chain

CDMO customer concentration risk — Yasser Lakdawala, M3

Partial

No significant concentration; 120+ customers; well-diversified; strong pipeline visibility; no patent cliff or major destocking foreseen

Laurus Bio H1 decline and H2 outlook — Arindam Mukerjee, Individual

Answered

Extra inventory as of Sept 30 for H3; utilized in coming quarter; capex investments ongoing; FCF healthy post-investments

Asset turns trajectory and capex efficiency — Tushar Manudhane, Motilal Oswal

Answered

Average asset turns 1.1x over 6 years; can move to 1.4x at peak; greenfield/brownfield capex will mature over time

Small molecule project pipeline and GLP-1 — Dhawal Khut, Jefferies

Partial

Multiple projects at NDA stage; cannot disclose specifics; programs range in scale; visibility good for next 18-24 months

Guidance

Forward guidance and management's confidence

CDMO to reach 50% of total revenue by FY30

Medium

Current CDMO ~35-40% of revenue; implies 10-15% CAGR on CDMO base; 4-year horizon; no interim milestones disclosed

Affordable Medicines to maintain double-digit growth

High

H1 growth 13%; order book expanding; pricing stable; emerging market tailwinds

Laurus Bio revenue inflection from mid-2027 as validation completes

Medium

Phase 1 fermentation facility operational by end FY27; commercial supplies expected in Q1 FY28; dependent on validation timeline

Gross margin 60%+ (currently 63%)

High

Achieved in H1; mix of CDMO growth and stable Affordable Medicines pricing support floor

EBITDA margin 30%+ (currently 34.5% in Q2)

High

Operational leverage and improved division/product mix expanding margins; R&D spend 4.3% of sales sustainable

FY27-'28 capex ₹3,000 Cr (raised from ₹2,000 Cr)

High

Primary focus: peptide manufacturing scale-up, Laurus Bio fermentation (500K-liter facility), KRKA JV, API capacity expansion

Risks the call surfaced

Ranked by how much they should concern a holder

Peptide validation execution

High

12-18 month validation timelines for peptide synthesis; clinical programs dependent on regulatory approvals; delay in validation cascades revenue inflection

Capex intensity and FCF pressure

Medium

₹3,000 Cr capex over FY27-'28 is aggressive; will strain FCF despite strong operating cash flow; ROI on peptide/Laurus Bio capex dependent on revenue inflection

Laurus Bio ramp-up execution

Medium

Laurus Bio Q2 revenue ₹29 Cr (down 16% YoY); facility validation delays or yield issues will push revenue recovery to FY28+, reducing near-term growth

CDMO customer concentration

Medium

Management states 'no significant concentration' but provides no granular detail; 125 programs spread across 100+ customers, but revenue contribution per customer unknown; risk of destocking or customer consolidation

Raw material and supply chain volatility

Low

Supply chain resilience maintained despite geopolitical headwinds; stable pricing achieved for ARV APIs; but commodity inflation or sourcing disruption could compress margins

Management

Score 7/10. Transparent on quarter results and guidance; disclosed Q3 softness upfront (positive). Evasive on commercially-sensitive details (customer concentration, project pipeline specifics, capex breakdown by modality). Disclosure quality mixed. Strong Q2 delivery (revenue ₹2,206 Cr, PAT ₹436 Cr) vs. guidance; margin guidance sustained (34.5% EBITDA); ROCE improving (17.7% FY26 → 22.5% H1). Capex raised to ₹3,000 Cr shows confidence but also replans prior guidance.

What to watch next
  • 1 · Q3 FY27

    Laurus Bio validation batch; facility qualification expected to resume revenue

  • 2 · Q4 FY27 / Q1 FY28

    Peptide manufacturing block commercial scale validation batches; first revenue generation timeline

  • 3 · Mid-2027

    KRKA formulation facility validation kick-off; JV contribution begins

Long-term trajectory (CDMO 50% by FY30, ROCE 19%→25%) is credible but depends on execution.

Informational and educational content only. Not investment advice.